摘要
目的：评价米氮平和艾司西酞普兰对老年抑郁症的疗效和安全性。方法对符合《中国精神障碍分类与诊断标准（第3版）》（CCMD‐3）抑郁症诊断标准的64例老年期抑郁症患者，随机分为两组，分别予米氮平和草酸艾司西酞普兰治疗。应用汉密尔顿抑郁量表（HAMD）和药物不良反应量表（TESS）在治疗前和治疗后第1、2、4、6周末评定其疗效和不良反应。结果米氮平组与草酸艾司西酞普兰组HAMD评分在1周后明显下降，与1周前差异有统计学意义（P＜0．01），1周末米氮平组HAMD评分低于草酸艾司西酞普兰组，但差异无统计学意义（P＞0．05）；米氮平的不良反应以头晕、嗜睡、便秘、食欲增加、体质量增加为主，草酸艾司西酞普兰以恶心呕吐、出汗、失眠、头痛为主。结论米氮平与草酸艾司西酞普兰对老年期抑郁患者疗效相仿。
Abstract
Objective To evaluate the efficacy and safety of mirtazapine combined with escitalopram oxalate for treating senile depression .Methods 64 cases of senile depression conforming to the CCMD‐3 diagnostic criteria of depression were randomly divided into two groups and treated by mirtazapine and escitalopram oxalate respectively . The Hamilton Depression Scale(HAMD) and the treatment emergent symptom scale(TESS) were adopted to evalu‐ate the efficacy and the adverse reactions before treatment and at 1 ,2 ,4 ,6 weekend after treatment .Results The HAMD scores after 1 week in the mirtazapine group and the escitalopram oxalate group were decreased significantly , and the difference had statistical significance (P<0 .01) ,the HAMD scores at 1 weekend in the mirtazapine group were lower than those in the escitalopram oxalate group ,but the difference had no statistical significance(P>0 .05);the adverse reactions of mirtazapine were mainly dizziness ,drowsiness ,constipation ,increased appetite and weight gain ,which of escitalopram oxalate were mainly nausea and vomiting ,sweating ,insomnia and headache .Conclusion Mirtazapine and escitalopram oxalate have the similar efficacy for treating senile depression .
国家科技期刊平台
NSTL
维普
万方数据